Publication:
Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax

Simple item page
dc.contributor.authorMallika Imwongen_US
dc.contributor.authorBruce Russellen_US
dc.contributor.authorRossarin Suwanarusken_US
dc.contributor.authorAlexis Nzilaen_US
dc.contributor.authorMara L. Leimanisen_US
dc.contributor.authorKanlaya Sriprawaten_US
dc.contributor.authorSupaporn Kaewpongsrien_US
dc.contributor.authorAung Pyae Phyoen_US
dc.contributor.authorGeorges Snounouen_US
dc.contributor.authorFrancois Nostenen_US
dc.contributor.authorLaurent Reniaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.contributor.otherAgency for Science, Technology and Research, Singaporeen_US
dc.contributor.otherKenya Medical Research Instituteen_US
dc.contributor.otherHopital Pitie Salpetriereen_US
dc.contributor.otherUniversite Pierre et Marie Curieen_US
dc.contributor.otherCentre for Clinical Vaccinology and Tropical Medicineen_US
dc.date.accessioned2018-05-03T08:37:16Z
dc.date.available2018-05-03T08:37:16Z
dc.date.issued2011-01-15en_US
dc.description.abstractResistance of vivax malaria to treatment with antifolates, such as pyrimethamine (Pyr), is spreading as mutations in the dihydrofolatereductase (dhfr) genes are selected and disseminated. We tested the antitumor drug methotrexate (MTX), a potent competitive inhibitor of dhfr, against 11 Plasmodium vivax isolates ex vivo, 10 of which had multiple dhfr mutations associated with Pyr resistance. Despite high-grade resistance to Pyr (median 50% inhibitory concentration [IC 50 ], 13,345 nM), these parasites were all highly susceptible to MTX (median IC 50 , 2.6 nM). Given its potency against Pyr-resistant P. vivax, the antimalarial potential of MTX deserves further investigation. © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.en_US
dc.identifier.citationJournal of Infectious Diseases. Vol.203, No.2 (2011), 207-210en_US
dc.identifier.doi10.1093/infdis/jiq024en_US
dc.identifier.issn00221899en_US
dc.identifier.other2-s2.0-79851491750en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12700
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79851491750&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleMethotrexate is highly potent against pyrimethamine-resistant Plasmodium vivaxen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79851491750&origin=inwarden_US

Files

Collections

Scopus 2011-2015